Repromedix Plan Ahead(TM) Test Offers Most Accurate Measurement of Women's
COLORADO SPRINGS, Colo., Jan. 24 /PRNewswire/ -- Reproductive Medicine & Fertility Center (RMFC) today announced it will be the first IVF center in the region to offer the Repromedix Plan Ahead(TM) test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs, which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
The Plan Ahead Report provides valuable directional information to women planning to have children after their late twenties. Women with faster biological clocks should seek further advice from fertility experts to help ensure that they can have the families they were hoping for.
"Reproductive Medicine & Fertility Center is proud of our national leadership in research and development in the field of reproductive technologies, and we always seek out the most advanced testing and treatment options for our patients," said RMFC founder and medical director Paul C. Magarelli, MD, Ph.D. "We believe in 'high tech with a personal touch,' so it is fitting that RMFC is the first IVF center in the Southwest to offer the Plan Ahead test, where we can provide women with the individual assessment of their own ovarian reserve to help them make more informed decisions about when to try for a baby."
Dr. Magarelli added, "Males have had a test to quantify their reproductive potentials by obtaining a semen analysis, while, until now, women have had to use surrogate testing, Day 3 FSH, Clomid challenge tests, etc. to give an estimate of their reproductive capacities. The Plan Ahead test helps couples -- the worried fertile -- get real facts about their eggs that they can use to shape a plan on the path to parenthood." Magarelli noted that RMFC "continues to lead in the development of cost-effective IVF care and we are proud to be the first in the Southwest to partner with Repromedix to provide all females a precise tool -- the Plan Ahead test -- for assessing their fertility potential."
"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer of Repromedix Corp. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."
Repromedix Corp., the Plan Ahead test co-developer and leading national diagnostic laboratory for fertility testing, chose Reproductive Medicine & Fertility Center to be one of a select number of IVF centers to debut the test. Repromedix will expand the Plan Ahead test launch to major markets across the United States throughout 2008.
Plan Ahead is now available to women in the Greater Denver area, and women interested in the Plan Ahead test can purchase a test online at http://www.planaheadtest.com/us or at Reproductive Medicine & Fertility Center, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the Plan Ahead test is $350.
Women interested in learning more about Plan Ahead should visit http://www.planaheadtest.com/us.
About Reproductive Medicine and Fertility Centers
Reproductive Medicine & Fertility Centers was established in 1998 with two goals in mind: "High Tech with a Personal Touch(TM)" and "Healing by Creating Families(TM)." RMFC is founded by Dr. Paul C. Magarelli, MD, Ph.D. Dr. Magarelli had a career that started as a Ph.D. in reproduction of marine animals and transitioned to humans, via medical school, to launch a network of RE&I centers (Colorado, New Mexico, California) that specialize in advanced reproductive technologies, novel financial programs, national leadership in research and development and a commitment to patient and academic excellence. Dr. Magarelli's team consists of Embryologist trained in the latest PGD technology, and Ph.D. administrators that develop cost-effective care. Dr. M. Mitwally, a patent holder in Aromatase Inhibitors, leads the research division of RMFC and RMFC is proud that we have been selected to host International RE&I Fellows in their career development. Our mottos reflect a commitment to the highest quality patient care while recognizing our responsibility to develop new and improved ways of helping our couples create families.
About Repromedix (http://www.repromedix.com)
Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.
Contact: Julie Dennehy, 508-533-8311 or firstname.lastname@example.org
|SOURCE Reproductive Medicine & Fertility Center|
Copyright©2008 PR Newswire.
All rights reserved